Please login to the form below

Getting it Right First Time: Building a Value-Based Contract Strategy

In their latest blog, Hanover Brussels Emma Eatwell and Josie Godfrey will explore how companies can efficiently and effectively increase the chances of securing value-based contracts that work for all.

The promise of innovative technologies is significant and is welcomed globally. The prospect of new therapies that could save and transform the lives of those living with severe conditions is eagerly anticipated, not only by patients but by all those within healthcare systems.

Less welcome are the associated challenges of a less stable evidence base at launch and potential high costs of these new technologies and therapies. Payers fear that so many therapies are being developed at such a fast pace that they cannot afford to introduce them into the system, despite their promised clinical benefit. Companies face uncertainty around reimbursement and the expectations for post-authorisation real world data generation. Patients also face the real possibility that treatments will be developed that could help them but that they are unable to access.

Affordability and the acceptance of real-world evidence are hot topics without clear solutions. Increasingly, innovative, value-based contracts (VBCs) are being agreed, with payers and companies looking at ways to bring therapies to patients. VBCs can focus on ensuring access, driving uptake, or both. They can address concerns about the evidence base, particularly when it comes to longer term outcomes in chronic or progressive conditions. They can also address barriers in infrastructure, capacity, diagnosis and affordability. The more complex the VBC, the more difficult it can be to agree, requiring significant resource from both companies and payers to develop. As they become more frequent, particularly for innovative therapies, we anticipate a shift from payers towards standardising VBCs. However, this does not mean one approach for all.

Recently we have seen successful launches of innovative therapies, but they can often take a long time and uptake may be slower than anticipated, something we have seen even with the highly effective Zolgensma for Spinal Muscular Atrophy. As VBCs become more common, companies are generally taking one of three approaches: a single global VBC strategy regardless of market, a region-by-region strategy or a country-by-country approach.

None of these approaches fully consider the external environment across countries, or the broader landscape. Instead, we recognise that there are commonalities between countries across the world that may not readily map onto geographical regions – Europe alone will require more than one type of VBC to address different payer preferences.

To develop global strategies and the tools that will best support local teams achieve success, global market access teams need to understand the external environment across countries, as well as the broader landscape, how this is likely to change and how the company can influence any such change. By mapping out the similarities and differences between markets, companies can move to more tailored access approaches that recognise the commonalities and differences between markets, regardless of geography.

Global teams will succeed where they are able to identify a small number of market archetypes in terms of their readiness to agree VBCs and the types of agreement that will fit well within their healthcare systems, their policy priorities, the current provision in the specific therapeutic area and capacity to deliver the new therapy.

This will enable global teams to identify a limited number of approaches to VBCs for an asset and the markets where they are most likely to succeed. Global teams can provide parameters for local teams to work within, to select the right VBC strategy first time, increasing the chance of securing a VBC that works for all stakeholders and brings products to the patients who need them.

7th March 2022


Company Details

Hanover Communications

+44 (0)20 7400 4480

Contact Website

Riverside House
Southwark Bridge House
United Kingdom

Latest content on this profile

Femtech: Transforming the future of women's healthcare
Femtech is potentially the most important development in health care right now. Women's health has been under-researched and overlooked for successive generations - it's time that government and industry get ready to deliver.
Hanover Communications
VPAS: The importance of making the right arguments, even in challenging times
With key workers’ strikes, inflation, and immense pressure on public services, arguing for a more generous pricing settlement for the pharmaceuticals industry could not be tougher. Read our Health Director James Mole’s thoughts on the support needed to protect the UK life sciences’ ambitions, despite the challenging backdrop.
Hanover Communications
Putting prevention at the heart of the future of the NHS
Prioritising the prevention of cardiovascular disease (CVD) should be at the heart of plans to safeguard the long-term sustainability of the NHS. Unfortunately, action in this area has to date not matched ambition, putting thousands of patients’ lives – and the future of the health system – at risk.
Hanover Communications
Action on Anti-microbial resistance: Will the UK rise to the challenge
Timely and effective antimicrobials are the cornerstone of our healthcare systems, providing life-saving treatment and supporting vital services like routine operations, transplants and cancer treatment. We are three years into the UK Government’s 20-Year Vision for Antimicrobial Resistance (AMR), and the Department of Health and Social Care recently launched a consultation for the next iteration of the AMR National Action Plan (2024-2029). However, latest figures show that AMR is still on the rise. Is UK policy ambitious enough to drive innovation in AMR, and is the Government on track to contain, control and mitigate AMR by 2040?
Hanover Communications
Winter and workforce woes: challenges facing the new Secretary of State for Health and Social Care
For the third time this year, the NHS and social care has a new Secretary of State. The appointment must now signal stability following a period of political turbulence, as we head into what health leaders are describing as the toughest winter to date. Backlogs, delayed discharges, ambulance and A&E pressures, and crumbling NHS estates will remain top of Steve Barclay’s priority list in the coming weeks and months ahead. However, he will also need to address the longstanding workforce issues that hold back both the NHS and social care sector. Only dealing with these structural challenges will ensure the health and care system is operationally fit for winters to come.
Hanover Communications
A new 10-year cancer plan: Will the government be able to deliver what the sector needs?
The Truss Government has committ­ed to developing a new 10-year cancer plan. But set against the backdrop of the Secretary of States priorities, what real value can the sector expect a new cancer plan to deliver? What questions need addressing to drive impactful change for patients? Will there be funding available to support the transformation?  We will explore the state of play of cancer care in England and assess the main priorities, including how they align with wider NHS challenges. We will set out the difficult choices that a new plan must confront to enable prioritisation of this complex disease area and consider the balance between taking action to impact patients now versus initiatives to benefit patients of the future.
Hanover Communications